ClinicalTrials.gg
CompletedNCT01359150Updated Mar 29, 2013Results posted

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

A Phase 2 interventional study of CP-690,550 and placebo in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 57 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-29.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.

Enrollment
20th of 43
223 · median 170
Started
2011
with 1 other
Phase 2
12 of 43
2 open now
Registered
19th of 43
by date
Lead sponsor
25 of 43
Pfizer

Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 2 that started in 2011, is one of 12 in phase 2, and was the 19th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tofacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

A Randomized, Double Blind, Placebo Controlled Phase 2 Study To assess the Immune Response Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid Arthritis receiving CP-690,550 with and Without background Methotrexate

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of RA by satisfying at least four of the seven criteria.
  • The subject must have active disease at both screening and baseline

Exclusion criteria

Exclusion Criteria:

  • History of any documented influenza or pneumococcal infection within the last 3 months.
  • Receipt of any vaccine within 1 month prior to the initial study drug administration (CP-690,550 or placebo CP-690,550).
  • If a subject has received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of initial study drug administration.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).

    CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.

    Drug: CP-690,550

  • Placebo comparator
    Treatment Group 2:Placebo CP-690,550 (100 subjects).

    Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.

    Drug: placebo

Interventions

  • Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).

  • Drugplacebo

    Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64)

    Satisfactory humoral response to the pneumococcal vaccine was defined as greater than or equal to (\>=) 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in at least 6 of 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.

    Time frame: Day 64 (End of Study [EOS])

  2. Percentage of Participants With Satisfactory Humoral Response to the Seasonal Influenza Vaccine at Visit 3 (Day 64)

    Satisfactory humoral response to the influenza vaccine was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.

    Time frame: Day 64 (EOS)

Secondary outcomes

  1. Percentage of Participants Who Responded to Each of the 12 Pneumococcal Antigens

    Response to the pneumococcal vaccine (seroconversion) was defined as \>= 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in each of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.

    Time frame: Day 64 (EOS)

  2. Percentage of Participants Who Responded to Each of the 3 Influenza Antigens

    Response to the influenza vaccine (seroconversion) was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in each of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.

    Time frame: Day 64 (EOS)

  3. Percentage of Participants With Protective Antibody Titers to the Seasonal Influenza Vaccine

    Seroprotection was defined as achieving protective antibody titers to the influenza vaccine as measured by a hemagglutination inhibition (HAI) assay titer of \>= 1:40 in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.

    Time frame: Day 64 (EOS)

  4. Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Day 29)

    Geometric mean fold rises (GMFRs) for the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. Confidence intervals (CIs) for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.

    Time frame: Day 64 (EOS)

  5. Geometric Mean Fold Rise (GMFR) of Anti-Influenza Antibody Levels to Each of the Influenza Antigens Above Vaccination Baseline Values (Day 29)

    GMFRs for the 3 influenza antigens (B, H1N1, H3N2) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.

    Time frame: Day 64 (EOS)

  6. Geometric Mean Concentrations (GMC) of Anti-Pneumococcal Antibody

    Antibody geometric mean concentration (GMC) for 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated.

    Time frame: Day 64 (EOS)

  7. Geometric Mean Titer (GMT) of Anti-Influenza Antibody

    Antibody geometric mean titer (GMT) for 3 influenza antigens antigens (B, H1N1, H3N2) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMT and corresponding 2-sided 95% confidence intervals (CI) were evaluated.

    Time frame: Day 64 (EOS)

07

Results

Posted Mar 29, 2013

Participant flow

Participant flow — Overall Study
MilestoneCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Started112111
Completed105106
Not completed75
Withdrew: Lack of efficacy11
Withdrew: Withdrawal by subject11
Withdrew: Adverse event43
Withdrew: Other10

Outcome measures

PrimaryPercentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64)

Satisfactory humoral response to the pneumococcal vaccine was defined as greater than or equal to (\>=) 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in at least 6 of 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.

Time frame:
Day 64 (End of Study [EOS])
Reported as:
Number · percentage of participants
Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64)
percentage of participantsCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Regardless MTX use (n=102,98)45.1 (35.224 to 55.264)68.4 (58.196 to 77.394)
With BG MTX use (n=57,55)31.6 (19.905 to 45.243)61.8 (47.726 to 74.591)
Without BG MTX use (n=45,43)62.2 (46.541 to 76.232)76.7 (61.369 to 88.245)
PrimaryPercentage of Participants With Satisfactory Humoral Response to the Seasonal Influenza Vaccine at Visit 3 (Day 64)

Satisfactory humoral response to the influenza vaccine was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.

Time frame:
Day 64 (EOS)
Reported as:
Number · percentage of participants
Percentage of Participants With Satisfactory Humoral Response to the Seasonal Influenza Vaccine at Visit 3 (Day 64)
percentage of participantsCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Regardless MTX use (n=102,98)56.9 (46.682 to 66.634)62.2 (51.885 to 71.844)
With BG MTX use (n=57,55)50.9 (37.29 to 64.37)58.2 (44.106 to 71.345)
Without BG MTX use (n=45,43)64.4 (48.78 to 78.132)67.4 (51.456 to 80.924)
SecondaryPercentage of Participants Who Responded to Each of the 12 Pneumococcal Antigens

Response to the pneumococcal vaccine (seroconversion) was defined as \>= 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in each of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.

Time frame:
Day 64 (EOS)
Reported as:
Number · percentage of participants
Percentage of Participants Who Responded to Each of the 12 Pneumococcal Antigens
percentage of participantsCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Regardless MTX use, 1 (n=102,98)59.8 (49.63 to 69.393)69.4 (59.265 to 78.302)
Regardless MTX use, 14 (n=102,98)52 (41.844 to 61.961)61.2 (50.849 to 70.903)
Regardless MTX use, 18C (n=102,98)59.8 (49.63 to 69.393)70.4 (60.338 to 79.205)
Regardless MTX use, 19A (n=102,98)32.4 (23.424 to 42.337)46.9 (36.778 to 57.289)
Regardless MTX use, 19F (n=102,98)35.3 (26.086 to 45.38)56.1 (45.732 to 66.133)
Regardless MTX use, 23F (n=102,98)40.2 (30.607 to 50.37)58.2 (47.766 to 68.054)
Regardless MTX use, 3 (n=102,98)38.2 (28.787 to 48.386)54.1 (43.714 to 64.196)
Regardless MTX use, 4 (n=102,98)58.8 (48.644 to 68.477)65.3 (55.02 to 74.64)
Regardless MTX use, 5 (n=102,98)28.4 (19.938 to 38.218)38.8 (29.097 to 49.151)
Regardless MTX use, 6B (n=102,98)36.3 (26.982 to 46.386)54.1 (43.714 to 64.196)
Regardless MTX use, 7F (n=102,98)58.8 (48.644 to 68.477)65.3 (55.02 to 74.64)
Regardless MTX use, 9V (n=102,98)45.1 (35.224 to 55.264)58.2 (47.766 to 68.054)
With BG MTX use, 1 (n=57,55)57.9 (44.084 to 70.857)61.8 (47.726 to 74.591)
With BG MTX use, 14 (n=57,55)47.4 (33.985 to 61.035)56.4 (42.322 to 69.696)
With BG MTX use, 18C (n=57,55)49.1 (35.63 to 62.71)58.2 (44.106 to 71.345)
With BG MTX use, 19A (n=57,55)19.3 (10.047 to 31.911)40 (27.023 to 54.093)
With BG MTX use, 19F (n=57,55)28.1 (16.973 to 41.543)49.1 (35.354 to 62.929)
With BG MTX use, 23F (n=57,55)24.6 (14.127 to 37.761)49.1 (35.354 to 62.929)
With BG MTX use, 3 (n=57,55)24.6 (14.127 to 37.761)49.1 (35.354 to 62.929)
With BG MTX use, 4 (n=57,55)52.6 (38.965 to 66.015)56.4 (42.322 to 69.696)
With BG MTX use, 5 (n=57,55)28.1 (16.973 to 41.543)29.1 (17.63 to 42.898)
With BG MTX use, 6B (n=57,55)29.8 (18.429 to 43.403)47.3 (33.653 to 61.196)
With BG MTX use, 7F (n=57,55)49.1 (35.63 to 62.71)56.4 (42.322 to 69.696)
With BG MTX use, 9V (n=57,55)33.3 (21.401 to 47.065)49.1 (35.354 to 62.929)
Without BG MTX use, 1 (n=45,43)62.2 (46.541 to 76.232)79.1 (63.958 to 89.956)
Without BG MTX use, 14 (n=45,43)57.8 (42.15 to 72.343)67.4 (51.456 to 80.924)
Without BG MTX use, 18C (n=45,43)73.3 (58.055 to 85.396)86 (72.068 to 94.702)
Without BG MTX use, 19A (n=45,43)48.9 (33.703 to 64.226)55.8 (39.875 to 70.922)
Without BG MTX use, 19F (n=45,43)44.4 (29.644 to 60.003)65.1 (49.073 to 78.992)
Without BG MTX use, 23F (n=45,43)60 (44.331 to 74.302)69.8 (53.875 to 82.818)
Without BG MTX use, 3 (n=45,43)55.6 (39.997 to 70.356)60.5 (44.41 to 75.023)
Without BG MTX use, 4 (n=45,43)66.7 (51.05 to 79.999)76.7 (61.369 to 88.245)
Without BG MTX use, 5 (n=45,43)28.9 (16.366 to 44.315)51.2 (35.465 to 66.695)
Without BG MTX use, 6B (n=45,43)44.4 (29.644 to 60.003)62.8 (46.725 to 77.025)
Without BG MTX use, 7F (n=45,43)71.1 (55.685 to 83.634)76.7 (61.369 to 88.245)
Without BG MTX use, 9V (n=45,43)60 (44.331 to 74.302)69.8 (53.875 to 82.818)
SecondaryPercentage of Participants Who Responded to Each of the 3 Influenza Antigens

Response to the influenza vaccine (seroconversion) was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in each of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.

Time frame:
Day 64 (EOS)
Reported as:
Number · percentage of participants
Percentage of Participants Who Responded to Each of the 3 Influenza Antigens
percentage of participantsCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Regardless MTX use, B (n=102,98)38.2 (28.787 to 48.386)52 (41.712 to 62.243)
Regardless MTX use, H1N1 (n=102,98)60.8 (50.62 to 70.305)63.3 (52.925 to 72.781)
Regardless MTX use, H3N2 (n=102,98)60.8 (50.62 to 70.305)69.4 (59.265 to 78.302)
With BG MTX use, B (n=57,55)35.1 (22.915 to 48.869)41.8 (28.655 to 55.894)
With BG MTX use, H1N1 (n=57,55)52.6 (38.965 to 66.015)58.2 (44.106 to 71.345)
With BG MTX use, H3N2 (n=57,55)57.9 (44.084 to 70.857)65.5 (51.419 to 77.763)
Without BG MTX use, B (n=45,43)42.2 (27.657 to 57.85)65.1 (49.073 to 78.992)
Without BG MTX use, H1N1 (n=45,43)71.1 (55.685 to 83.634)69.8 (53.875 to 82.818)
Without BG MTX use, H3N2 (n=45,43)64.4 (48.78 to 78.132)74.4 (58.828 to 86.481)
SecondaryPercentage of Participants With Protective Antibody Titers to the Seasonal Influenza Vaccine

Seroprotection was defined as achieving protective antibody titers to the influenza vaccine as measured by a hemagglutination inhibition (HAI) assay titer of \>= 1:40 in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.

Time frame:
Day 64 (EOS)
Reported as:
Number · percentage of participants
Percentage of Participants With Protective Antibody Titers to the Seasonal Influenza Vaccine
percentage of participantsCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Regardless MTX use (n=102,98)76.5 (67.043 to 84.305)91.8 (84.547 to 96.41)
With BG MTX use (n=57,55)64.9 (51.131 to 77.085)92.7 (82.413 to 97.983)
Without BG MTX use (n=45,43)91.1 (78.779 to 97.525)90.7 (77.865 to 97.407)
SecondaryGeometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Day 29)

Geometric mean fold rises (GMFRs) for the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. Confidence intervals (CIs) for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.

Time frame:
Day 64 (EOS)
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Day 29)
fold riseCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Regardless MTX use, 1 (n=89,92)4.75 (3.61 to 6.24)6.83 (4.94 to 9.46)
Regardless MTX use, 14 (n=101,96)2.68 (2.19 to 3.28)3.90 (3.05 to 4.99)
Regardless MTX use, 18C (n=101,98)3.10 (2.52 to 3.81)4.82 (3.76 to 6.18)
Regardless MTX use, 19A (n=102,98)1.80 (1.56 to 2.08)2.34 (1.99 to 2.75)
Regardless MTX use, 19F (n=102,95)2.04 (1.71 to 2.42)2.89 (2.40 to 3.49)
Regardless MTX use, 23F (n=102,98)2.00 (1.64 to 2.44)2.81 (2.34 to 3.36)
Regardless MTX use, 3 (n=101,94)2.11 (1.76 to 2.54)2.79 (2.31 to 3.38)
Regardless MTX use, 4 (n=96,89)3.10 (2.49 to 3.86)5.13 (3.94 to 6.67)
Regardless MTX use, 5 (n=101,98)1.72 (1.50 to 1.97)2.27 (1.91 to 2.70)
Regardless MTX use, 6B (n=102,98)1.90 (1.61 to 2.24)2.56 (2.12 to 3.10)
Regardless MTX use, 7F (n=102,97)3.19 (2.59 to 3.93)4.06 (3.27 to 5.04)
Regardless MTX use, 9V (n=102,98)2.27 (1.85 to 2.55)3.16 (2.59 to 3.86)
With BG MTX use, 1 (n=49,53)3.92 (2.77 to 5.54)4.51 (3.00 to 6.77)
With BG MTX use, 14 (n=56,54)2.37 (1.84 to 3.04)2.85 (2.19 to 3.72)
With BG MTX use, 18C (n=57,55)2.64 (2.05 to 3.41)3.23 (2.45 to 4.26)
With BG MTX use, 19A (n=57,55)1.51 (1.30 to 1.74)2.08 (1.67 to 2.59)
With BG MTX use, 19F (n=57,53)1.92 (1.51 to 2.44)2.29 (1.88 to 2.79)
With BG MTX use, 23F (n=57,55)1.66 (1.32 to 2.07)2.34 (1.88 to 2.91)
With BG MTX use, 3 (n=56,54)1.78 (1.39 to 2.27)2.43 (1.90 to 3.12)
With BG MTX use, 4 (n=53,50)2.92 (2.22 to 3.85)3.27 (2.51 to 4.25)
With BG MTX use, 5 (n=57,55)1.62 (1.35 to 1.95)1.99 (1.59 to 2.50)
With BG MTX use, 6B (n=57,55)1.60 (1.37 to 1.88)2.24 (1.79 to 2.81)
With BG MTX use, 7F (n=57,55)2.38 (1.89 to 2.98)3.46 (2.57 to 4.64)
With BG MTX use, 9V (n=57,55)1.87 (1.53 to 2.29)2.72 (2.08 to 3.54)
Without BG MTX use, 1 (n=40,39)6.01 (3.85 to 9.37)12.04 (7.34 to 19.74)
Without BG MTX use, 14 (n=45,42)3.14 (2.25 to 4.37)5.85 (3.81 to 8.99)
Without BG MTX use, 18C (n=44,43)3.80 (2.70 to 5.35)8.05 (5.37 to 12.08)
Without BG MTX use, 19A (n=45,43)2.27 (1.75 to 2.94)2.72 (2.13 to 3.47)
Without BG MTX use, 19F (n=45,42)2.19 (1.68 to 2.85)3.88 (2.78 to 5.43)
Without BG MTX use, 23F (n=45,43)2.54 (1.81 to 3.58)3.55 (2.63 to 4.78)
Without BG MTX use, 3 (n=45,40)2.61 (1.98 to 3.44)3.37 (2.49 to 4.55)
Without BG MTX use, 4 (n=43,39)3.32 (2.31 to 4.79)9.15 (5.85 to 14.29)
Without BG MTX use, 5 (n=44,43)1.86 (1.50 to 2.29)2.68 (2.04 to 3.52)
Without BG MTX use, 6B (n=45,43)2.36 (1.73 to 3.21)3.04 (2.19 to 4.21)
Without BG MTX use, 7F (n=45,42)4.62 (3.23 to 6.60)5.02 (3.65 to 6.90)
Without BG MTX use, 9V (n=45,43)2.63 (2.03 to 3.41)3.83 (2.82 to 5.19)
SecondaryGeometric Mean Fold Rise (GMFR) of Anti-Influenza Antibody Levels to Each of the Influenza Antigens Above Vaccination Baseline Values (Day 29)

GMFRs for the 3 influenza antigens (B, H1N1, H3N2) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.

Time frame:
Day 64 (EOS)
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) of Anti-Influenza Antibody Levels to Each of the Influenza Antigens Above Vaccination Baseline Values (Day 29)
fold riseCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Regardless MTX use, B (n=102,98)2.95 (2.32 to 3.75)3.90 (3.06 to 4.97)
Regardless MTX use, H1N1 (n=102,98)6.04 (4.59 to 7.95)9.50 (6.76 to 13.35)
Regardless MTX use, H3N2 (n=102,98)7.11 (5.18 to 9.75)9.06 (6.61 to 12.44)
With BG MTX use, B (n=57,55)2.84 (2.02 to 3.98)3.11 (2.27 to 4.26)
With BG MTX use, H1N1 (n=57,55)4.90 (3.43 to 7.00)7.54 (4.80 to 11.85)
With BG MTX use, H3N2 (n=57,55)5.69 (3.88 to 8.34)6.04 (4.18 to 8.73)
Without BG MTX use, B (n=45,43)3.11 (2.20 to 4.40)5.20 (3.57 to 7.57)
Without BG MTX use, H1N1 (n=45,43)7.88 (5.13 to 12.10)12.76 (7.56 to 21.53)
Without BG MTX use, H3N2 (n=45,43)9.43 (5.52 to 16.09)15.25 (9.06 to 25.66)
SecondaryGeometric Mean Concentrations (GMC) of Anti-Pneumococcal Antibody

Antibody geometric mean concentration (GMC) for 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated.

Time frame:
Day 64 (EOS)
Reported as:
Geometric mean · microgram/milliliter (mcg/mL)
Geometric Mean Concentrations (GMC) of Anti-Pneumococcal Antibody
microgram/milliliter (mcg/mL)CP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
11.81 (1.32 to 2.48)3.27 (2.34 to 4.58)
145.24 (3.85 to 7.12)6.40 (4.63 to 8.84)
18C2.53 (1.95 to 3.29)4.60 (3.48 to 6.09)
19A5.21 (4.15 to 6.54)8.57 (6.86 to 10.70)
19F2.59 (1.93 to 3.47)3.09 (2.28 to 4.19)
23F2.41 (1.86 to 3.11)3.55 (2.78 to 4.55)
30.66 (0.52 to 0.86)1.11 (0.86 to 1.43)
40.72 (0.54 to 0.97)1.07 (0.77 to 1.48)
54.05 (3.23 to 5.09)5.79 (4.60 to 7.30)
6B2.99 (2.34 to 3.83)4.75 (3.71 to 6.07)
7F3.28 (2.42 to 4.45)4.37 (3.36 to 5.67)
9V2.61 (2.11 to 3.23)4.06 (3.29 to 5.01)
SecondaryGeometric Mean Titer (GMT) of Anti-Influenza Antibody

Antibody geometric mean titer (GMT) for 3 influenza antigens antigens (B, H1N1, H3N2) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMT and corresponding 2-sided 95% confidence intervals (CI) were evaluated.

Time frame:
Day 64 (EOS)
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Anti-Influenza Antibody
titerCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
B33.39 (25.61 to 43.54)50.74 (39.82 to 64.64)
H1N186.40 (64.35 to 116.0)221.5 (161.4 to 304.0)
H3N2132.3 (97.65 to 179.1)244.0 (184.6 to 322.5)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 + Influenza and Pneumococcal Vaccine—4/112 (3.6%)17/112 (15.2%)
Placebo + Influenza and Pneumococcal Vaccine—1/111 (0.9%)17/111 (15.3%)
Most frequent serious events
Most frequent serious events
EventCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
CellulitisInfections and infestations0/1121/111
Atrial fibrillationCardiac disorders1/1120/111
Chest painGeneral disorders1/1120/111
PneumoniaInfections and infestations1/1120/111
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1120/111
Most frequent other events
Most frequent other events
EventCP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal Vaccine
Upper respiratory tract infectionInfections and infestations6/1128/111
HeadacheNervous system disorders5/1121/111
DiarrhoeaGastrointestinal disorders1/1124/111
Urinary tract infectionInfections and infestations3/1124/111
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/1123/111
DizzinessNervous system disorders3/1120/111
Sinus congestionRespiratory, thoracic and mediastinal disorders3/1120/111

Baseline characteristics

Age Continuous
Age Continuous(years)CP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal VaccineTotal
Mean52.7 ± 10.452.2 ± 11.152.4 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)CP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal VaccineTotal
Female8190171
Male312152
Number of Participants With Background (BG) Methotrexate (MTX) use
Number of Participants With Background (BG) Methotrexate (MTX) use(participants)CP-690,550 + Influenza and Pneumococcal VaccinePlacebo + Influenza and Pneumococcal VaccineTotal
With Background MTX use6262124
Without Background MTX use504999
08

Study locations

57 sites
  • Pfizer Investigational Site
    Gilbert, Arizona 85234, United States
  • Pfizer Investigational Site
    Paradise Valley, Arizona 85253, United States
  • Pfizer Investigational Site
    Jonesboro, Arkansas 72401, United States
  • Pfizer Investigational Site
    Fair Oaks, California 95628, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095, United States
  • Pfizer Investigational Site
    Roseville, California 95661, United States
  • Pfizer Investigational Site
    Upland, California 91786, United States
  • Pfizer Investigational Site
    Boulder, Colorado 80304, United States
  • Pfizer Investigational Site
    Trumbull, Connecticut 06611, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32216, United States
  • Pfizer Investigational Site
    Naples, Florida 34102, United States
  • Pfizer Investigational Site
    New Port Richey, Florida 34652, United States
  • Pfizer Investigational Site
    Port Richey, Florida 34668, United States
  • Pfizer Investigational Site
    Tampa, Florida 33613, United States
  • Pfizer Investigational Site
    Zephyrhills, Florida 33542, United States
  • Pfizer Investigational Site
    Morton Grove, Illinois 60053, United States
  • Pfizer Investigational Site
    Rockford, Illinois 61107, United States
  • Pfizer Investigational Site
    Vernon Hills, Illinois 60061, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67208, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40504, United States
  • Pfizer Investigational Site
    Cumberland, Maryland 21502, United States
  • Pfizer Investigational Site
    Leominster, Massachusetts 01453, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01605, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01608, United States
  • Pfizer Investigational Site
    Bingham Farms, Michigan 48025, United States
  • Pfizer Investigational Site
    Edina, Minnesota 55435, United States
  • Pfizer Investigational Site
    Columbia, Missouri 65203, United States
  • Pfizer Investigational Site
    Columbia, Missouri 65212, United States
  • Pfizer Investigational Site
    Lebanon, New Hampshire 03756, United States
  • Pfizer Investigational Site
    Albany, New York 12206, United States
  • Pfizer Investigational Site
    Binghamton, New York 13905, United States
  • Pfizer Investigational Site
    Olean, New York 14760, United States
  • Pfizer Investigational Site
    Rochester, New York 14618, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28210, United States
  • Pfizer Investigational Site
    Rocky Mount, North Carolina 27804, United States
  • Pfizer Investigational Site
    Minot, North Dakota 58701, United States
  • Pfizer Investigational Site
    Dayton, Ohio 45417, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • Pfizer Investigational Site
    Bethlehem, Pennsylvania 18015, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • Pfizer Investigational Site
    Wyomissing, Pennsylvania 19610, United States
  • Pfizer Investigational Site
    Greenville, South Carolina 29601, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37909, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Mesquite, Texas 75150, United States
  • Pfizer Investigational Site
    Seattle, Washington 98104, United States
  • Pfizer Investigational Site
    Seattle, Washington 98122, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98405, United States
  • Pfizer Investigational Site
    Vancouver, Washington 98664, United States
  • Pfizer Investigational Site
    Clarksburg, West Virginia 26301, United States
  • Pfizer Investigational Site
    Cieszyn, 43-400, Poland
  • Pfizer Investigational Site
    Koscian, 64-000, Poland
  • Pfizer Investigational Site
    Poznan, 60-773, Poland
  • Pfizer Investigational Site
    Torun, 87-100, Poland
  • Pfizer Investigational Site
    Warszawa, 02-256, Poland
  • Pfizer Investigational Site
    Wroclaw, 50-088, Poland
09

References and documents

Publications

  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. PubMed 33127856 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31. PubMed 28143815 ↗
  • Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20. PubMed 25795907 ↗
  • Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779. PubMed 25047021 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2011
First posted
May 24, 2011
Start
Sep 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Mar 29, 2013
Last update
Mar 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01359150
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 24, 2011
Start date
Sep 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Mar 29, 2013
Last update
Mar 29, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion